Lably
Skip to content

Oral polio vaccine AIDS hypothesis

Disproven medical conspiracy theory

  • 10 min read
  • 4 chapters

Related on Lably

Through Hypothesis, HIV/AIDS and Phylogenetics

Though a small number of experts initially thought this hypothesis was plausible, later data analyses in molecular biology and phylogenetic studies contradict the OPV AIDS hypothesis. Scientific consensus regards the hypothesis as lacking evidence or disproven. A 2004 Nature article has described the hypothesis as "refuted".

Background: polio vaccines

Two vaccines are used throughout the world to combat poliomyelitis. The first, a polio vaccine developed by Jonas Salk, is an inactivated poliovirus vaccine (IPV), consisting of a mixture of three wild, virulent strains of poliovirus, grown in a type of monkey kidney tissue culture (Vero cell line), and made noninfectious by formaldehyde treatment. The second vaccine, an oral polio vaccine (OPV), is a live-attenuated vaccine, produced by the passage of the virus through non-human cells at a sub-physiological temperature. The passage of virus produces mutations within the viral genome, and hinders the virus's ability to infect nervous tissue.

Both vaccines have been used for decades to induce immunity to polio, and to stop the spread of the infection. However, OPV has several advantages; because the vaccine is introduced in the gastrointestinal tract, the primary site of poliovirus infection and replication, it closely mimics a natural infection. OPV also provides long lasting immunity, and stimulates the production of polio neutralizing antibodies in the pharynx and gut. Hence, OPV not only prevents paralytic poliomyelitis, but also, when given in sufficient doses, can stop a threatening epidemic. Other benefits of OPV include ease of administration, low cost and suitability for mass vaccination campaigns.

Oral polio vaccine

Oral polio vaccines were developed in the late 1950s by several groups, including those led by Albert Sabin, Hilary Koprowski and H. R. Cox. A poliovirus type 1 strain called SM was reported in 1954. A less virulent version of the SM strain was reported by Koprowski in 1957. The name of the vaccine strain was "CHAT" after "Charlton", the name of the child who was the donor of the precursor virus. The Sabin, Koprowski and Cox vaccines were clinically tested in millions of individuals and found to be safe and effective. Because monkey trials found fewer side effects with the Sabin vaccine, in the early 1960s, the Sabin vaccine was licensed in the US and its use supported by the World Health Organization.

Between 1957 and 1960, Koprowski's vaccine was administered to roughly one million people in the Belgian territories, now the Democratic Republic of the Congo, Rwanda and Burundi. In 1960, Koprowski wrote in the British Medical Journal, "The Belgian Congo trials have enlarged considerably and ... more vaccination campaigns organized in several provinces of the Belgian Congo are raising the number of vaccinated individuals into the millions."(p. 90) Koprowski and his group also published a series of detailed reports on the vaccination of 76,000 children under the age of five (and European adults) in the area of Leopoldville (now Kinshasa) in Belgian Congo from 1958 to 1960; these reports begin with an overview, next a review of safety and efficacy, then a 21-month follow-up and final report.

Vaccine production

In the 1950s, before dangers inherent to the process were well controlled, seed stocks of vaccines were occasionally transported to distant regions, then standard tissue culture methods were used to amplify the virus at local production facilities. Biologic products, chiefly kidney cells for cultures and blood serum for media, were sometimes harvested from local primates and used in the production process if wild or captive populations of appropriate species were available. In South Africa, African green monkey tissue was used to amplify the Sabin vaccine. In French West Africa and Equatorial Africa, baboons were used to amplify a vaccine from the Pasteur Institute. In Poland, the CHAT vaccine was amplified using Asian macaques.

Sign in to keep reading

3 more chapters are free with a Lably account.

More in Health